{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:59:51Z","timestamp":1790618391113,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","award":["Ep\/v047329\/1"],"award-info":[{"award-number":["Ep\/v047329\/1"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Polymeric excipients play an important role in a cocrystal formulation to act as precipitation inhibitors to maximize the potential. Otherwise, a stable form of the parent drug will be recrystallized on the dissolving cocrystal surface and\/or in the bulk solution during the cocrystal dissolution process, negating the solubility advantage. The objectives of this work were to investigate the potential of using combined polymers to maximise the dissolution performance of surface precipitation pharmaceutical cocrystals.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The dissolution performance of a highly soluble flufenamic acid and nicotinamide (FFA-NIC) cocrystal has been systematically studied with predissolved or powder mixed with a single polymer, including a surface precipitation inhibitor [i.e., copolymer of vinylpyrrolidone (60%) \/vinyl acetate (40%) (PVP-VA)] and two bulk precipitation inhibitors [i.e., polyethylene glycol (PEG) and Soluplus (SLP)], or binary polymers combinations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A single polymer of PVP-VA prevented the FFA surface precipitation for an enhanced dissolution performance of FFA-NIC cocrystal. Unfortunately, it cannot sustain the supersaturated FFA concentration in the bulk solution. A combination of two polymers of PVP-VA and SLP has shown a synergistic inhibition effect to enhance the dissolution advantage of FFA-NIC cocrystal.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The dissolution of a cocrystal with surface precipitation of the parent drug can be described as: i) the cocrystal surface contacting the dissolution medium; ii) the cocrystal surface dissolving; iii) the parent drug precipitation on the dissolving surface; and iv) the parent drug particles redissolving. A combination of two types of polymers can be used to maximise the cocrystal performance in solution.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract\n<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s11095-023-03532-x","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T19:02:35Z","timestamp":1684177355000},"page":"2051-2069","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Optimisation of Pharmaceutical Cocrystal Dissolution Performance through a Synergistic Precipitation Inhibition"],"prefix":"10.1007","volume":"40","author":[{"given":"Kejing","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9532-9049","authenticated-orcid":false,"given":"Mingzhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"issue":"1\u20132","key":"3532_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2011.07.037","volume":"419","author":"N Qiao","year":"2011","unstructured":"Qiao N, Li M, Schlindwein W, Malek N, Davies A, Trappitt G. Pharmaceutical cocrystals: An overview. Int J Pharm. 2011;419(1\u20132):1\u201311.","journal-title":"Int J Pharm"},{"issue":"3","key":"3532_CR2","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.drudis.2018.11.023","volume":"24","author":"ON Kavanagh","year":"2019","unstructured":"Kavanagh ON, Croker DM, Walker GM, Zaworotko MJ. Pharmaceutical cocrystals: from serendipity to design to application. Drug Discovery Today. 2019;24(3):796\u2013804.","journal-title":"Drug Discovery Today"},{"issue":"9","key":"3532_CR3","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1002\/jps.24003","volume":"103","author":"MD Eddleston","year":"2014","unstructured":"Eddleston MD, Madusanka N, Jones W. Cocrystal Dissociation in the Presence of Water: A General Approach for Identifying Stable Cocrystal Forms. J Pharm Sci. 2014;103(9):2865\u201370.","journal-title":"J Pharm Sci"},{"issue":"7","key":"3532_CR4","doi-asserted-by":"publisher","first-page":"4523","DOI":"10.1021\/acs.cgd.0c00321","volume":"20","author":"M Aljohani","year":"2020","unstructured":"Aljohani M, McArdle P, Erxleben A. Influence of Excipients on Cocrystal Stability and Formation. Cryst Growth Des. 2020;20(7):4523\u201332.","journal-title":"Cryst Growth Des"},{"issue":"12","key":"3532_CR5","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1021\/acs.molpharmaceut.7b00712","volume":"14","author":"M Guo","year":"2017","unstructured":"Guo M, Wang K, Qiao N, F\u00e1bi\u00e1n L, Sadiq G, Li M. Insight into Flufenamic Acid Cocrystal Dissolution in the Presence of a Polymer in Solution: from Single Crystal to Powder Dissolution. Mol Pharm. 2017;14(12):4583\u201396.","journal-title":"Mol Pharm"},{"issue":"2","key":"3532_CR6","first-page":"517","volume":"17","author":"P Kirubakaran","year":"2020","unstructured":"Kirubakaran P, Wang K, Rosbottom I, Cross RBM, Li M. Understanding the Effects of a Polymer on the Surface Dissolution of Pharmaceutical Cocrystals Using Combined Experimental and Molecular Dynamics Simulation Approaches. Mol Pharm. 2020;17(2):517\u201329.","journal-title":"Mol Pharm"},{"key":"3532_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101566","volume":"56","author":"M Omori","year":"2020","unstructured":"Omori M, Uekusa T, Oki J, Inoue D, Sugano K. Solution-mediated phase transformation at particle surface during cocrystal dissolution. J Drug Deliv Sci Technol. 2020;56: 101566.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"10","key":"3532_CR8","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.1021\/acs.molpharmaceut.0c00587","volume":"17","author":"M Omori","year":"2020","unstructured":"Omori M, Watanabe T, Uekusa T, Oki J, Inoue D, Sugano K. Effects of Coformer and Polymer on Particle Surface Solution-Mediated Phase Transformation of Cocrystals in Aqueous Media. Mol Pharm. 2020;17(10):3825\u201336.","journal-title":"Mol Pharm"},{"key":"3532_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2021.103029","volume":"67","author":"M Shigemura","year":"2022","unstructured":"Shigemura M, Omori M, Sugano K. Polymeric precipitation inhibitor differently affects cocrystal surface and bulk solution phase transformations. J Drug Deliv Sci Technol. 2022;67: 103029.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3532_CR10","doi-asserted-by":"crossref","unstructured":"Omori M, Yamamoto H, Matsui F, Sugano K. Dissolution Profiles of Carbamazepine Cocrystals with Cis-Trans Isomeric Coformers. Pharm Res. 2022.","DOI":"10.1007\/s11095-022-03209-x"},{"issue":"15","key":"3532_CR11","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1039\/C6CE00263C","volume":"18","author":"S Qiu","year":"2016","unstructured":"Qiu S, Lai J, Guo M, Wang K, Lai X, Desai U, et al. Role of polymers in solution and tablet-based carbamazepine cocrystal formulations. CrystEngComm. 2016;18(15):2664\u201378.","journal-title":"CrystEngComm"},{"issue":"9","key":"3532_CR12","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1007\/s11095-014-1326-2","volume":"31","author":"M Li","year":"2014","unstructured":"Li M, Qiu S, Lu Y, Wang K, Lai X, Rehan M. Investigation of the Effect of Hydroxypropyl Methylcellulose on the Phase Transformation and Release Profiles of Carbamazepine-Nicotinamide Cocrystal. Pharm Res. 2014;31(9):2312\u201325.","journal-title":"Pharm Res"},{"issue":"3","key":"3532_CR13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1021\/mp0700108","volume":"4","author":"JF Remenar","year":"2007","unstructured":"Remenar JF, Peterson ML, Stephens PW, Zhang Z, Zimenkov Y, Hickey MB. Celecoxib: Nicotinamide Dissociation: Using Excipients To Capture the Cocrystal\u2019s Potential. Mol Pharm. 2007;4(3):386\u2013400.","journal-title":"Mol Pharm"},{"issue":"1","key":"3532_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijpharm.2014.12.049","volume":"479","author":"S Qiu","year":"2015","unstructured":"Qiu S, Li M. Effects of coformers on phase transformation and release profiles of carbamazepine cocrystals in hydroxypropyl methylcellulose based matrix tablets. Int J Pharm. 2015;479(1):118\u201328.","journal-title":"Int J Pharm"},{"key":"3532_CR15","doi-asserted-by":"crossref","unstructured":"Alinda P, Shi K, Li M. Nucleation of Supersaturated Flufenamic Acid Cocrystal Solutions in the Presence of a Polymer. Cryst Growth Des. 2022.","DOI":"10.1021\/acs.cgd.2c00323"},{"issue":"2","key":"3532_CR16","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1208\/s12248-016-9865-6","volume":"18","author":"MM Knopp","year":"2016","unstructured":"Knopp MM, Nguyen JH, Mu H, Langguth P, Rades T, Holm R. Influence of Copolymer Composition on In Vitro and In Vivo Performance of Celecoxib-PVP\/VA Amorphous Solid Dispersions. AAPS J. 2016;18(2):416\u201323.","journal-title":"AAPS J"},{"issue":"9","key":"3532_CR17","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1021\/acs.molpharmaceut.6b00612","volume":"13","author":"M Guo","year":"2016","unstructured":"Guo M, Wang K, Hamill N, Lorimer K, Li M. Investigating the Influence of Polymers on Supersaturated Flufenamic Acid Cocrystal Solutions. Mol Pharm. 2016;13(9):3292\u2013307.","journal-title":"Mol Pharm"},{"key":"3532_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ejpb.2016.08.016","volume":"108","author":"M Alhijjaj","year":"2016","unstructured":"Alhijjaj M, Belton P, Qi S. An investigation into the use of polymer blends to improve the printability of and regulate drug release from pharmaceutical solid dispersions prepared via fused deposition modeling (FDM) 3D printing. Eur J Pharm Biopharm. 2016;108:111\u201325.","journal-title":"Eur J Pharm Biopharm"},{"issue":"6","key":"3532_CR19","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3109\/21691401.2012.762369","volume":"41","author":"M-S Kim","year":"2013","unstructured":"Kim M-S. Soluplus-coated colloidal silica nanomatrix system for enhanced supersaturation and oral absorption of poorly water-soluble drugs. Artif Cells Nanomedicine Biotechnol. 2013;41(6):363\u20137.","journal-title":"Artif Cells Nanomedicine Biotechnol"},{"issue":"5","key":"3532_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1208\/s12249-020-01684-2","volume":"21","author":"S Alshehri","year":"2020","unstructured":"Alshehri S, Imam SS, Altamimi MA, Hussain A, Shakeel F, Alshehri A. Stimulatory Effects of Soluplus\u00ae on Flufenamic Acid \u03b2-Cyclodextrin Supramolecular Complex: Physicochemical Characterization and Pre-clinical Anti-inflammatory Assessment. AAPS PharmSciTech. 2020;21(5):145.","journal-title":"AAPS PharmSciTech"},{"issue":"5","key":"3532_CR21","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1021\/cg801039j","volume":"9","author":"DJ Good","year":"2009","unstructured":"Good DJ, Rodr\u00edguez-Hornedo N. Solubility Advantage of Pharmaceutical Cocrystals. Cryst Growth Des. 2009;9(5):2252\u201364.","journal-title":"Cryst Growth Des"},{"issue":"12","key":"3532_CR22","doi-asserted-by":"publisher","first-page":"8056","DOI":"10.1021\/acsomega.0c05558","volume":"6","author":"Y Gao","year":"2021","unstructured":"Gao Y, Glennon B, He Y, Donnellan P. Dissolution Kinetics of a BCS Class II Active Pharmaceutical Ingredient: Diffusion-Based Model Validation and Prediction. ACS Omega. 2021;6(12):8056\u201367.","journal-title":"ACS Omega"},{"issue":"24","key":"3532_CR23","doi-asserted-by":"publisher","first-page":"9872","DOI":"10.1021\/ja302601f","volume":"134","author":"V L\u00f3pez-Mej\u00edas","year":"2012","unstructured":"L\u00f3pez-Mej\u00edas V, Kampf JW, Matzger AJ. Nonamorphism in Flufenamic Acid and a New Record for a Polymorphic Compound with Solved Structures. J Am Chem Soc. 2012;134(24):9872\u20135.","journal-title":"J Am Chem Soc"},{"issue":"2","key":"3532_CR24","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s10953-010-9642-6","volume":"40","author":"L Zapa\u0142a","year":"2011","unstructured":"Zapa\u0142a L. Potentiometric Studies on the Equilibria of Flufenamic Acid in Aqueous Solutions and in Two-phase Organic Solvent + Water Systems. J Solution Chem. 2011;40(2):198\u2013210.","journal-title":"J Solution Chem"},{"issue":"12","key":"3532_CR25","doi-asserted-by":"publisher","first-page":"5645","DOI":"10.1021\/acs.cgd.5b01417","volume":"15","author":"\u00d6 Almarsson","year":"2015","unstructured":"Almarsson \u00d6, Vadas EB. Molecules, Materials, Medicines (M3): Linking Molecules to Medicines through Pharmaceutical Material Science. Cryst Growth Des. 2015;15(12):5645\u20137.","journal-title":"Cryst Growth Des"},{"issue":"9","key":"3532_CR26","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1002\/jps.23025","volume":"101","author":"K Greco","year":"2012","unstructured":"Greco K, Bogner R. Solution-Mediated Phase Transformation: Significance During Dissolution and Implications for Bioavailability. J Pharm Sci. 2012;101(9):2996\u20133018.","journal-title":"J Pharm Sci"},{"issue":"10","key":"3532_CR27","doi-asserted-by":"publisher","first-page":"6323","DOI":"10.1021\/acs.cgd.2c00787","volume":"22","author":"A Alvani","year":"2022","unstructured":"Alvani A, Shayanfar A. Solution Stability of Pharmaceutical Cocrystals. Cryst Growth Des. 2022;22(10):6323\u201337.","journal-title":"Cryst Growth Des"},{"issue":"2","key":"3532_CR28","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1021\/cg0503346","volume":"6","author":"SJ Nehm","year":"2006","unstructured":"Nehm SJ, Rodr\u00edguez-Spong B, Rodr\u00edguez-Hornedo N. Phase Solubility Diagrams of Cocrystals Are Explained by Solubility Product and Solution Complexation. Cryst Growth Des. 2006;6(2):592\u2013600.","journal-title":"Cryst Growth Des"},{"issue":"9","key":"3532_CR29","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1021\/acs.molpharmaceut.9b00501","volume":"16","author":"Y Huang","year":"2019","unstructured":"Huang Y, Kuminek G, Roy L, Cavanagh KL, Yin Q, Rodr\u00edguez-Hornedo N. Cocrystal Solubility Advantage Diagrams as a Means to Control Dissolution, Supersaturation, and Precipitation. Mol Pharm. 2019;16(9):3887\u201395.","journal-title":"Mol Pharm"},{"issue":"12","key":"3532_CR30","doi-asserted-by":"publisher","first-page":"6719","DOI":"10.1021\/acs.cgd.6b01434","volume":"16","author":"H Yamashita","year":"2016","unstructured":"Yamashita H, Sun CC. Harvesting Potential Dissolution Advantages of Soluble Cocrystals by Depressing Precipitation Using the Common Coformer Effect. Cryst Growth Des. 2016;16(12):6719\u201321.","journal-title":"Cryst Growth Des"},{"issue":"8","key":"3532_CR31","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1021\/acs.molpharmaceut.2c00122","volume":"19","author":"T Cogo Machado","year":"2022","unstructured":"Cogo Machado T, Kavanagh ON, Gon\u00e7alves Cardoso S, Rodr\u00edguez-Hornedo N. Synchronization of Cocrystal Dissolution and Drug Precipitation to Sustain Drug Supersaturation. Mol Pharm. 2022;19(8):2765\u201375.","journal-title":"Mol Pharm"},{"issue":"3","key":"3532_CR32","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ejpb.2012.10.005","volume":"83","author":"N Qiao","year":"2013","unstructured":"Qiao N, Wang K, Schlindwein W, Davies A, Li M. In situ monitoring of carbamazepine\u2013nicotinamide cocrystal intrinsic dissolution behaviour. Eur J Pharm Biopharm. 2013;83(3):415\u201326.","journal-title":"Eur J Pharm Biopharm"},{"issue":"9","key":"3532_CR33","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1002\/jps.22250","volume":"99","author":"EH Lee","year":"2010","unstructured":"Lee EH, Byrn SR. Stabilization of metastable flufenamic acid by inclusion of mefenamic acid: Solid solution or epilayer? J Pharm Sci. 2010;99(9):4013\u201322.","journal-title":"J Pharm Sci"},{"issue":"9","key":"3532_CR34","doi-asserted-by":"publisher","first-page":"5215","DOI":"10.1021\/acs.cgd.2c00323","volume":"22","author":"P Alinda","year":"2022","unstructured":"Alinda P, Shi K, Li M. Nucleation of Supersaturated Flufenamic Acid Cocrystal Solutions in the Presence of a Polymer. Cryst Growth Des. 2022;22(9):5215\u201328.","journal-title":"Cryst Growth Des"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-023-03532-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-023-03532-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-023-03532-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T06:06:20Z","timestamp":1692770780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-023-03532-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["3532"],"URL":"https:\/\/doi.org\/10.1007\/s11095-023-03532-x","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"28 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}